Concert Pharmaceuticals Inc. announced Phase 1 data of CTP-354, a novel, potentially first-in-class, non-sedating, once-daily oral treatment for spasticity. In this multiple ascending dose trial, no sedation or ataxia was observed with CTP-354 and the drug was generally well tolerated across all dose cohorts.
Concert expects to initiate a Phase 2 clinical trial evaluating CTP-354 in patients with spasticity associated with spinal cord injury by the end of 2014..... Read More - http://www.ms-uk.org/emergingtherapies
Positive data from multiple dose phase1 trial of CTP-354
Positive data from multiple dose phase1 trial of CTP-354
MS-UK - http://www.ms-uk.org/
-
- Similar Topics
- Replies
- Views
- Last post
-
- 0 Replies
- 2171 Views
-
Last post by NHE
-
- 0 Replies
- 10246 Views
-
Last post by NHE
-
- 8 Replies
- 7155 Views
-
Last post by Algis
-
- 0 Replies
- 2031 Views
-
Last post by NHE
-
- 0 Replies
- 10626 Views
-
Last post by NHE
-
- 1 Replies
- 1736 Views
-
Last post by frodo
-
- 0 Replies
- 1525 Views
-
Last post by frodo
-
- 0 Replies
- 1460 Views
-
Last post by frodo
-
- 0 Replies
- 1672 Views
-
Last post by frodo